Vertex Pharmaceuticals Aktie
WKN: 882807 / ISIN: US92532F1003
04.11.2024 22:41:37
|
Vertex Pharmaceuticals Inc. Q3 Profit Increases, Beats Estimates
(RTTNews) - Vertex Pharmaceuticals Inc. (VRTX) released a profit for its third quarter that increased from the same period last year and beat the Street estimates.
The company's bottom line came in at $1.045 billion, or $4.01 per share. This compares with $1.035 billion, or $3.97 per share, in last year's third quarter.
Excluding items, Vertex Pharmaceuticals Inc. reported adjusted earnings of $1.143 billion or $4.38 per share for the period.
Analysts on average had expected the company to earn $4.14 per share, according to figures compiled by Thomson Reuters. Analysts' estimates typically exclude special items.
The company's revenue for the quarter rose 11.6% to $2.771 billion from $2.483 billion last year.
Vertex Pharmaceuticals Inc. earnings at a glance (GAAP) :
-Earnings (Q3): $1.045 Bln. vs. $1.035 Bln. last year. -EPS (Q3): $4.01 vs. $3.97 last year. -Revenue (Q3): $2.771 Bln vs. $2.483 Bln last year.
-Guidance: Full year revenue guidance: $10.8 - $10.9 Bln

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Vertex Pharmaceuticals Inc.mehr Nachrichten
22:35 |
Minuszeichen in New York: NASDAQ Composite liegt letztendlich im Minus (finanzen.at) | |
22:35 |
S&P 500 aktuell: S&P 500 zum Handelsende im Minus (finanzen.at) | |
22:35 |
NASDAQ-Handel NASDAQ 100 zum Handelsende im Minus (finanzen.at) | |
20:05 |
Schwacher Handel: Das macht der NASDAQ Composite am Dienstagnachmittag (finanzen.at) | |
20:05 |
Minuszeichen in New York: Das macht der S&P 500 nachmittags (finanzen.at) | |
20:05 |
Verluste in New York: NASDAQ 100 präsentiert sich am Dienstagnachmittag schwächer (finanzen.at) | |
18:03 |
Minuszeichen in New York: S&P 500 legt mittags den Rückwärtsgang ein (finanzen.at) | |
18:03 |
Dienstagshandel in New York: NASDAQ Composite gibt nach (finanzen.at) |
Analysen zu Vertex Pharmaceuticals Inc.mehr Analysen
Aktien in diesem Artikel
Vertex Pharmaceuticals Inc. | 338,70 | -16,79% |
|